600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Closed 04-24 15:00:00
56.05
-0.35
-0.62%
High56.75Low55.32Vol55.78M
Open56.50D1 Closing56.40Amplitude2.54%
Mkt Cap372.00BTradable Cap357.54BTotal Shares6.64B
T/O3.13BT/O Rate0.87%Tradable Shares6.38B
P/B5.85ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

UBS Reaffirms Buy Rating on Hengrui Pharma, Raises Target Price to HK$97.4
Deep News  ·  04-25 10:51
UBS Reaffirms Buy Rating on Hengrui Pharma, Raises Target Price to HK$97.4
Citigroup Initiates Coverage on Hengrui Pharma with Buy Rating and HK$134 Target
Deep News  ·  04-25 10:20
Citigroup Initiates Coverage on Hengrui Pharma with Buy Rating and HK$134 Target
Citigroup Initiates Coverage on Hengrui Pharma with Buy Rating, Sets HK$134 Price Target
Stock News  ·  04-24 16:05
Citigroup Initiates Coverage on Hengrui Pharma with Buy Rating, Sets HK$134 Price Target
UBS Increases Hengrui Pharma Price Target to HK$97.4, Reiterates Buy Rating
Stock News  ·  04-24 11:07
UBS Increases Hengrui Pharma Price Target to HK$97.4, Reiterates Buy Rating
Hengrui Pharmaceuticals' Innovative Pipeline Seen as Undervalued -- Market Talk
Dow Jones  ·  04-23 18:19
Hengrui Pharmaceuticals' Innovative Pipeline Seen as Undervalued -- Market Talk
Jiangsu Hengrui Shares Could Re-Rate Higher With Future Outlicensing Deals -- Market Talk
Dow Jones  ·  04-23
Jiangsu Hengrui Shares Could Re-Rate Higher With Future Outlicensing Deals -- Market Talk
HENGRUI PHARMA Shares Climb Over 5% Following Robust Q1 Earnings Report
Stock News  ·  04-23
HENGRUI PHARMA Shares Climb Over 5% Following Robust Q1 Earnings Report
Key Hong Kong Stock Announcements: Hengrui Pharma Q1 Net Profit Rises 21.78% YoY; Seres Plans Up to RMB 2 Billion A-Share Buyback
Stock News  ·  04-23
Key Hong Kong Stock Announcements: Hengrui Pharma Q1 Net Profit Rises 21.78% YoY; Seres Plans Up to RMB 2 Billion A-Share Buyback
Hong Kong Market Insights: State Council Pushes for Green Transport Infrastructure; Hengrui Pharma Q1 Net Profit Rises 21.78%
Stock News  ·  04-23
Hong Kong Market Insights: State Council Pushes for Green Transport Infrastructure; Hengrui Pharma Q1 Net Profit Rises 21.78%
Jiangsu Hengrui Q1 net profit climbs 21.78% to RMB 2.3 billion
Reuters  ·  04-22
Jiangsu Hengrui Q1 net profit climbs 21.78% to RMB 2.3 billion
Hengrui Pharma Reports Q1 2026 Results With Revenue and Net Profit Growth
THOMSON REUTERS  ·  04-22
Hengrui Pharma Reports Q1 2026 Results With Revenue and Net Profit Growth
China's top drugmaker Hengrui profit in line with expectations in first quarter of 2026
Reuters  ·  04-22
China's top drugmaker Hengrui profit in line with expectations in first quarter of 2026
Jiangsu Hengrui Pharmaceuticals Q1 Net Profit up 21.8% Y/Y
THOMSON REUTERS  ·  04-22
Jiangsu Hengrui Pharmaceuticals Q1 Net Profit up 21.8% Y/Y
HENGRUI PHARMA's HRS9531 Injection Receives Clinical Trial Approval
Stock News  ·  04-20
HENGRUI PHARMA's HRS9531 Injection Receives Clinical Trial Approval
HENGRUI PHARMA to Distribute Final Dividend of RMB 2 per 10 Shares on May 27
Deep News  ·  04-20
HENGRUI PHARMA to Distribute Final Dividend of RMB 2 per 10 Shares on May 27
HENGRUI PHARMA to Distribute Final Dividend of RMB 2 per 10 Shares on May 27
Stock News  ·  04-17
HENGRUI PHARMA to Distribute Final Dividend of RMB 2 per 10 Shares on May 27
HENGRUI PHARMA to Distribute Final Dividend of RMB 2 per 10 Shares on May 27
Stock News  ·  04-17
HENGRUI PHARMA to Distribute Final Dividend of RMB 2 per 10 Shares on May 27
Jiangsu Hengrui declares 2025 final dividend of RMB 2 per 10 shares
Reuters  ·  04-17
Jiangsu Hengrui declares 2025 final dividend of RMB 2 per 10 shares
Jiangsu Hengrui files directors list with Hong Kong Stock Exchange
Reuters  ·  04-16
Jiangsu Hengrui files directors list with Hong Kong Stock Exchange
HENGRUI PHARMA's Injectable SHR-A2102 Designated as Breakthrough Therapy for Second Time
Stock News  ·  04-16
HENGRUI PHARMA's Injectable SHR-A2102 Designated as Breakthrough Therapy for Second Time

Introduction

Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
Issue price:
11.98